Table 1. Main demographic features of the SALIR cohort (n = 320).
| Age (years, mean ± SD) | 47.3 | 8.7 | |
| Sex (n, %) | male | 235 | 73.4 |
| female | 85 | 26.6 | |
| HIV transmission category (n, %) | IDU | 106 | 33.1 |
| Heterosexual | 124 | 38.8 | |
| MSM | 68 | 24.4 | |
| Other or unknown | 12 | 3.8 | |
| CDC stage C (n, %) | 144 | 45.0 | |
| CD4 count (cells/µL, n, %) | <200 | 143 | 44.8 |
| 200–350 | 89 | 27.9 | |
| >350 | 88 | 27.3 | |
| Past ARV regimens | 1–5 | 72 | 22.5 |
| 6–8 | 85 | 26.6 | |
| 9–12 | 94 | 29.4 | |
| 13 | 69 | 21.6 | |
| ART duration before study entry (years,mean ± SD) | 16.9 | 5.5 | |
| Genotypic Sensitivity Score (mean ± SD) | 2.0 | 0.8 | |
| HCV or HBV positive (n, %) | 111 | 34.7 | |
| Total cholesterol (mean ± SD) | 181 | 49 | |
| HDL cholesterol (mean ± SD) | 46 | 25 | |
| Triglycerides (median, IQR) | 170 | 118–275 | |
| AST (median, IQR) | 32 | 22–48 | |
| ALT (median, IQR) | 36 | 22–55 | |
SD = Standard Deviation, IDU = intravenous drug user, MSM = male having sex with males, IQR = interquartile range, ARV = antiretroviral, ART = antiretroviral therapy, HDL = high density lipoprotein, AST = aspartate aminotransferase, ALT = alanine aminotransferase.